法尼醇X受体激动剂对非酒精性脂肪性肝炎治疗作用研究进展  

Progress on the treatment of metabolic dysfunction-associated fatty liver disease by farnesol X receptor agonist

作　　者：王霆宇[1] 魏尉[1] 钟黄 刘菲 黄忠[1] 龚航 Wang Tingyu;Wei Wei;Zhong Huang;Liu Fei;Huang Zhong;Gong Hang(Department of Gastroenterology,Zigong First People’s Hospital,Zigong 643000,Sichuan Province,China)

机构地区：[1]自贡市第一人民医院消化内科,四川自贡643000

出　　处：《中国肝脏病杂志（电子版）》2023年第1期6-11,共6页Chinese Journal of Liver Diseases：Electronic Version

基　　金：自贡市科学技术局科研课题(自贡市第一人民医院医学科学院项目)(2020YXY09);自贡市卫生健康委员会科研课题(20zd002)。

摘　　要：代谢相关脂肪性肝病(metabolic dysfunction-associated fatty liver disease,MAFLD)的全球患病率为20%~40%,伴随着沉重的疾病负担和晚期疾病相关的高病死率,目前尚无批准治疗MAFLD的标准药物。法尼醇X受体(farnesoid X receptor,FXR)具有调控糖脂代谢和改善胰岛素抵抗的作用,其中奥贝胆酸作为FXR激动剂,已被多项研究证实可改善MAFLD患者的肝组织学特征。本文主要阐述FXR激动剂的作用机制和研究现状以供临床参考。The global prevalence of metabolic dysfunction-associated fatty liver disease(MAFLD)is 20%~40%,and with a heavy disease burden and a high mortality rate associated with advanced disease,there is still no approved standard drug for the treatment of MAFLD.farnesoid X receptor(FXR)can regulate glycolipid metabolism and improve insulin resistance.Obercholic acid,as an FXR agonist,has been confirmed to improve the hepatic histological characteristics of patients with MAFLD in some studies.This paper described the mechanism of action of FXR agonist and its current research status for clinical reference.

关 键 词：法尼醇X受体激动剂 代谢相关脂肪性肝病 奥贝胆酸 

分 类 号：R575.1[医药卫生—消化系统]